Abstract: The present disclosure discloses a soft-start protection circuit, comprising: a protection chip, a first switch tube, a second switch tube, a third switch tube, a fourth switch tube, a first capacitor, a first resistor, a second resistor, a third resistor, a fourth resistor, a fifth resistor, a sixth resistor and a seventh resistor. In the soft-start protection circuit of the present disclosure, the voltage of a voltage input end and the control end voltage of the first switch tube may be monitored; therefore, when there is a change in the two voltages, correct turn-on and turn-off actions may be performed in the soft-start protection circuit, increasing the accuracy of protection and at the same time reducing the turn-on speed of switch tubes to a certain extent, thus effectively reducing the impact of an impulse current on components and systems. Correspondingly, the present disclosure further discloses a circuit protection integrated chip.

Abstract: A microspheric ionomer having a cross-linked structure, a preparation method therefor, applications thereof, and a preparation system thereof. The ionomer comprises structure units A represented by formula (1), structure units B represented by formula (2), and a cross-linking structure provided by a cross-linking agent, M being separately selected from H, a metal cation, and a straight chain, a saturated alkyl of branched or ring-shaped C1-C20, R being H or a methyl; and metal cations are introduced to part of structure units A in the ionomer. The ionomer shows an outstanding effect on nucleation of PET, serves as a nucleating agent for PET modification, so as to obtain a corresponding PET composition.

Abstract: Disclosed herein is a device for detecting nucleic acids, the device comprising a CRISPR-Cas13a-mediated graphene field-effect transistor comprising a source electrode; a drain electrode; a gate electrode; a detection channel; where the channel comprises a CRISPR-Cas13a-mediated graphene layer; where Cas13a is operative to function as an effector protein that targets a specific RNA sequence for cleavage based on a recognition of the RNA sequence by crRNA. Disclosed herein too is a device for detecting nucleic acids, the device comprising a CRISPR-Cas12a-mediated graphene field-effect transistor comprising a source electrode; a drain electrode; a gate electrode; a detection channel; where the channel comprises a CRISPR-Cas12a-mediated graphene layer; where Cas12a is operative to function as an effector protein that targets a specific DNA sequence for cleavage based on a recognition of the DNA sequence by crRNA.

Abstract: This invention relates to novel compounds according to Formula (I) which are antagonists of MrgX2, to pharmaceutical compositions containing them, and to their use in therapy for the treatment of MrgX2-mediated diseases and disorders.

Abstract: A method for early diagnosis of keratoconus based on multi-modal data considers a mutual relationship between both eyes using four refractive maps for corneas of the both eyes and absolute corneal elevation data, and combines the deep convolutional network method, the traditional support vector machine (SVM) method in machine learning, and the elevation map enhancement method with adjustable best-fit-sphere (BFS) to identify sensitivity and specificity of a focus and balance the sensitivity and specificity. With multi-dimensional comprehensive judgment of a keratoconus morbidity with a patient as a unit, combined with binocular data including both manual selection features and deep network learning from big data, the diagnosis method has higher robustness and accuracy.

Abstract: A method for early diagnosis of keratoconus based on multi-modal data considers a mutual relationship between both eyes using four refractive maps for corneas of the both eyes and absolute corneal elevation data, and combines the deep convolutional network method, the traditional support vector machine (SVM) method in machine learning, and the elevation map enhancement method with adjustable best-fit-sphere (BFS) to identify sensitivity and specificity of a focus and balance the sensitivity and specificity. With multi-dimensional comprehensive judgment of a keratoconus morbidity with a patient as a unit, combined with binocular data including both manual selection features and deep network learning from big data, the diagnosis method has higher robustness and accuracy.

Abstract: An automatic traction device for a lower limb fracture osteosynthesis includes a chassis structure, a lower leg supporting structure and an upper leg supporting structure connected two by two. The automatic traction device further includes a tibia distal position adjusting device, for adjusting a position and an angle of a distal end of a tibia, on the lower leg supporting structure and close to the first end portion of the lower leg supporting structure; and a tibia proximal position adjusting device, for adjusting a position and an angle of a proximal end of a tibia, on the lower leg supporting structure and close to the second end portion of the lower leg supporting structure.

Abstract: This invention relates to novel compounds according to Formula (I) which are antagonists of MrgX2, to pharmaceutical compositions containing them, and to their use in therapy for the treatment of MrgX2-mediated diseases and disorders.

Abstract: An automatic traction device for a lower limb fracture osteosynthesis includes a chassis structure, a lower leg supporting structure and an upper leg supporting structure connected two by two. The automatic traction device further includes a tibia distal position adjusting device, for adjusting a position and an angle of a distal end of a tibia, on the lower leg supporting structure and close to the first end portion of the lower leg supporting structure; and a tibia proximal position adjusting device, for adjusting a position and an angle of a proximal end of a tibia, on the lower leg supporting structure and close to the second end portion of the lower leg supporting structure.

Abstract: The present disclosure relates to systems and methods for personalized recommendation. The systems may perform the methods to detect an application executing on the user terminal. The systems may perform the methods to communicate with the application with respect to a service request sent by the user via the user terminal. The systems may perform the methods to obtain one or more current context-related features and one or more current-user-related features with respect to the user, and a plurality of candidate recommendation items. The systems may perform the methods to select a target recommendation item from the plurality of candidate recommendation items based on the one or more current context-related features and the one or more current user-related features, using a trained recommendation model, and provide the target recommendation item to the application to generate a presentation, on a display of the user terminal of the user.

Abstract: Disclosed are 4-amino-2-butenamides of Formula (I) having pharmacological activity, pharmaceutical compositions containing them, and methods for the treatment of diseases mediated by the cathepsin C enzyme such as chronic obstructive pulmonary disease.

Abstract: The invention is directed to novel indole carboxamide compounds. Specifically, the invention is directed to compounds according to formula (I): wherein R1, R2, R3, R4, and m are as defined herein. The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKK?) activity, such as rheumatoid arthritis, asthma, rhinitis, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Abstract: The invention is directed to novel indole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula (I): wherein R1, R2, R3, R4, and m are as defined herein. The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKK?) activity, such as rheumatoid arthritis, asthma, rhinitis, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Abstract: This invention relates to novel compounds, compositions and combinations thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

Abstract: This invention relates to novel compounds, compositions and combinations thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

Abstract: The invention is directed to novel indole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula (I): wherein R1, R2, R3, R4, and m are as defined herein. The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKK?) activity, such as rheumatoid arthritis, asthma, rhinitis, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Abstract: Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.

Abstract: The invention is directed to novel indolecarboxamide derivatives. Specifically, the invention is directed to compounds according to formula (I): where R1, R2, R3 and X are defined below. These compounds are useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKK?) activity, in particular in the treatment and prevention of disorders mediated by IKK2 mechanisms including inflammatory and tissue repair disorders. Such disorders include rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease).